Palisade Bio (NASDAQ:PALI) Director Robert Jr. Baltera Buys 20,000 Shares

Key Points

• Director Robert Jr. Baltera bought 20,000 Palisade Bio shares on July 6 at an average price of $2.05, a $41,000 purchase that lifted his holdings to 386,904 shares. He also made several additional purchases earlier in the week.
• Palisade Bio stock was trading around $2.05, near its 50-day and 200-day moving averages, with a market cap of about $355.8 million. The stock has ranged from a 52-week low of $0.53 to a high of $2.86.
• The company recently reported a quarterly EPS loss of $0.05, slightly worse than analysts expected, while Wall Street maintains a generally positive view with an average Buy rating and an average target price of $8.83.

Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) Director Robert Jr. Baltera purchased 20,000 shares of the company's stock in a transaction that occurred on Monday, July 6th. The shares were purchased at an average cost of $2.05 per share, with a total value of $41,000.00. Following the completion of the acquisition, the director owned 386,904 shares in the company, valued at $793,153.20. The trade was a 5.45% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Robert Jr. Baltera also recently made the following trade(s):

• On Tuesday, July 7th, Robert Jr. Baltera acquired 30,000 shares of Palisade Bio stock. The stock was purchased at an average cost of $2.03 per share, for a total transaction of $60,900.00.
• On Thursday, July 2nd, Robert Jr. Baltera bought 10,000 shares of Palisade Bio stock. The shares were purchased at an average cost of $1.98 per share, with a total value of $19,800.00.
• On Wednesday, July 1st, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The stock was acquired at an average price of $1.98 per share, for a total transaction of $39,600.00.

Palisade Bio Price Performance

Palisade Bio stock traded down $0.03 during midday trading on Wednesday, hitting $2.05. The company's stock had a trading volume of 3,270,900 shares, compared to its average volume of 4,120,142. The company has a market cap of $355.84 million, a price-to-earnings ratio of -2.03 and a beta of 1.50. Palisade Bio, Inc. has a 1-year low of $0.53 and a 1-year high of $2.86. The company has a 50-day moving average price of $1.91 and a two-hundred day moving average price of $1.92.

Palisade Bio (NASDAQ:PALI - Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Sell-side analysts forecast that Palisade Bio, Inc. will post -0.25 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on PALI. Wall Street Zen raised Palisade Bio from a "sell" rating to a "hold" rating in a research note on Sunday. Oppenheimer set a $7.00 price target on shares of Palisade Bio in a report on Tuesday, June 30th. LADENBURG THALM/SH SH raised shares of Palisade Bio to a "strong-buy" rating in a research note on Thursday, June 25th. HC Wainwright reaffirmed a "buy" rating and issued a $2.00 target price on shares of Palisade Bio in a report on Tuesday, June 30th. Finally, Weiss Ratings raised Palisade Bio from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, June 29th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $8.83.

Institutional Investors Weigh In On Palisade Bio

Several hedge funds have recently modified their holdings of PALI. Perceptive Advisors LLC bought a new stake in Palisade Bio during the 4th quarter worth $28,318,000. Commodore Capital LP acquired a new stake in shares of Palisade Bio during the fourth quarter valued at about $26,896,000. Janus Henderson Group PLC bought a new stake in shares of Palisade Bio during the fourth quarter worth about $24,822,000. RA Capital Management L.P. acquired a new position in shares of Palisade Bio in the fourth quarter valued at approximately $16,742,000. Finally, Eversept Partners LP acquired a new position in shares of Palisade Bio in the fourth quarter valued at approximately $12,670,000. Institutional investors and hedge funds own 11.79% of the company's stock.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.